News › Clinical Practice, Industry News, Patient Care

Profound for the Treatment of Cellulite in 2017

December 28, 2016

In November, Syneron Medical Ltd. announced that it received a new FDA 510(k) clearance of its minimally invasive, fractional radiofrequency (RF) microneedling device Profound.
The new indication is for using the device with the 75o SubQ handpiece and cartridge to improve the appearance of cellulite.
“Profound is the first and most effective single minimally invasive treatment for cellulite that provides a meaningful improvement,” Macrene Alexiades, M.D., PhD, tells Cosmetic Surgery Times.
Dr. Alexiades, who is director and president of the Dermatology & Laser Surgery Center of New York, was an investigator of a recent multi-center clinical study of Profound, which examined and analyzed the dimples and/or undulation irregularities in the thighs of 50 women with Fitzpatrick skin types I – III.
Read more at Cosmetic Surgery Times >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Federal Bill Would Establish New Ownership and Management Requirements for Medical Practices
    • CBS News Investigation Raises Concerns About Unapproved Retatrutide Sales
    • Beyond Either/Or: Building Integrated Treatment Plans with Energy-Based Devices and Injectables
    • FDA Approves Belotero Volume and Belotero Intense
    • Ad IntellX Becomes Platinum Vendor Affiliate with the American Med Spa Association
Advertisement